Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are...
iRhythm is a digital healthcare company redefin...
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Solid Biosciences is a life science company focused solely on finding meaningful t...
Solid Biosciences is a life science company foc...
SINTX Technologies is a commercial biomaterial company focused on using its silico...
SINTX Technologies is a commercial biomaterial ...
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
Join the National Investor Network and get the latest information with your interests in mind.